Mural Oncology plc Total Liabilities
Mural Oncology plc total liabilities. Based on the latest financial reports, Mural Oncology plc (MURA) has total liabilities worth $10.57 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Mural Oncology plc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Mural Oncology plc (2021–2024)
Total liabilities of Mural Oncology plc from 2021 to 2024. This chart illustrates how Mural Oncology plc's total liabilities have evolved over time, based on quarterly financial data.
Mural Oncology plc Competitors by Total Liabilities
The table below lists competitors of Mural Oncology plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Parlem Telecom Companyia de Telecomunicacions S.A.
MC:PAR
|
Spain | €48.76 Million |
|
RATH Aktiengesellschaft
VI:RAT
|
Austria | €72.27 Million |
|
Fundamental Global Inc.
NASDAQ:FGNX
|
USA | $20.35 Million |
|
FIT INVEST JSC
VN:FIT
|
Vietnam | ₫2.86 Trillion |
|
Plastikkart Akilli Kart Iletisim Sistemleri Sanayi ve Ticaret AS
IS:PKART
|
Turkey | TL329.77 Million |
|
Minetech Resources Bhd
KLSE:7219
|
Malaysia | RM112.06 Million |
|
GSE Co. Ltd
KQ:053050
|
Korea | ₩113.08 Billion |
|
Drax Group PLC
LSE:DRX
|
UK | GBX3.02 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down Mural Oncology plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see MURA total asset value.
Liquidity & Leverage Metrics
Mural Oncology plc Total Liabilities Ratios Explained
Mural Oncology plc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mural Oncology plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mural Oncology plc (2021–2024)
The table below shows the annual total liabilities of Mural Oncology plc from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $28.89 Million | -23.82% |
| 2023-12-31 | $37.93 Million | -31.55% |
| 2022-12-31 | $55.41 Million | +4.56% |
| 2021-12-31 | $52.99 Million | -- |
About Mural Oncology plc
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cut… Read more